Share on StockTwits

Novartis (NYSE:NVS)’s share price reached a new 52-week high during mid-day trading on Monday , Analyst Ratings Network reports. The company traded as high as $84.00 and last traded at $83.72, with a volume of 1,252,222 shares. The stock had previously closed at $82.65.

A number of analysts have recently weighed in on NVS shares. Analysts at UBS AG initiated coverage on shares of Novartis in a research note on Thursday, January 9th. They set a “buy” rating on the stock. Analysts at Jefferies Group downgraded shares of Novartis from a “buy” rating to a “hold” rating in a research note on Thursday, January 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $82.33.

The stock’s 50-day moving average is $80.54 and its 200-day moving average is $77.56. The company has a market cap of $202.6 billion and a P/E ratio of 22.34.

Novartis (NYSE:NVS) last released its earnings data on Wednesday, January 29th. The company reported $1.20 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.27 by $0.07. The company had revenue of $15.08 billion for the quarter, compared to the consensus estimate of $15.16 billion. During the same quarter in the prior year, the company posted $1.27 earnings per share. The company’s quarterly revenue was up 1.7% on a year-over-year basis. Analysts expect that Novartis will post $5.37 EPS for the current fiscal year.

The company also recently declared a annual dividend, which is scheduled for Tuesday, March 11th. Shareholders of record on Monday, March 3rd will be given a dividend of $2.7186 per share. This represents a yield of 3.48%. The ex-dividend date of this dividend is Thursday, February 27th.

Novartis AG is a Switzerland-based holding that, through its subsidiaries, is engaged in the research, development, manufacture and marketing of healthcare products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.